^
    Back
    Association details:
    Biomarker:KIT mutation
    Cancer:Cutaneous Melanoma
    Drug:imatinib (Bcr-abl inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/26/2022
    Excerpt:
    Melanoma: Cutaneous...SYSTEMIC THERAPY FOR METASTATIC AND URESECTABLE DISEASE...SECOND-LINE OR SUBSEQUENT THERAPY...Useful in certain circumstances...Imatinib for tumors with activating KIT mutations
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Ipilimumab and Imatinib Mesylate in Advanced Cancer

    Excerpt:
    ...For expansion cohorts, patients must have metastatic or unresectable gastrointestinal stromal tumor (GIST), melanoma, or uncategorized tumors with tumor biopsies that are positive for c-KIT mutations by polymerase chain reaction (PCR) or immunohistochemistry (IHC)....
    Trial ID:
    NCT01738139
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

    Excerpt:
    ...- Patients must have either a true amplification of 4q12 or a detectable mutation of c-KIT...
    Trial ID:
    NCT00470470